Evan Y. Yu
University of Washington · 618 works · 23,097 citations · h-index 61
Top works
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- Integrative Clinical Genomics of Advanced Prostate Cancer
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
- Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
- Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
- The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer
- Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
- Delays in radical cystectomy for muscle‐invasive bladder cancer
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
- Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer